Mizuho Medy
4595.TTSE STANDARDPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥11.3bn | ¥11.4bn | ¥11.0bnr | ¥17.6bnr | ¥13.1bnr | ¥4.2bnr |
| Operating income | ¥4.6bn | ¥4.9bn | ¥5.2bnr | ¥11.1bn | ¥6.7bn | — |
| Ordinary income | ¥4.7bn | ¥5.2bn | ¥5.3bnr | ¥11.1bnr | ¥6.7bnr | ¥415mr |
| Total assets | ¥22.4bn | ¥20.7bn | ¥18.9bnr | ¥19.1bnr | ¥12.2bnr | ¥6.1bnr |
| Net assets / equity | ¥18.7bn | ¥17.4bn | ¥15.7bnr | ¥14.3bnr | ¥8.0bnr | ¥3.8bnr |
| Operating cash flow | ¥2.0bn | ¥3.3bn | ¥4.0bnr | ¥6.2bnr | ¥5.6bnr | ¥295mr |
| EPS (basic) | ¥179.84 | ¥198.12 | ¥198.13r | ¥411.47r | ¥252.86r | ¥16.08r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 69 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 117 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 69 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 117 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 69 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 43 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 117 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 47 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 71 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 43 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 117 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 47 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 71 figures · EDINET |
22 more reports are still being processed.